Edition:
United Kingdom

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

42.56CHF
18 Apr 2019
Change (% chg)

CHF-1.70 (-3.84%)
Prev Close
CHF44.26
Open
CHF44.30
Day's High
CHF44.30
Day's Low
CHF42.40
Volume
83,731
Avg. Vol
51,008
52-wk High
CHF73.95
52-wk Low
CHF38.60

Select another date:

Tue, Feb 19 2019

BRIEF-Basilea Pharmaceutica FY Net Loss Widens To CHF 31.4 Million

* BASILEA REPORTS STRONG REVENUE GROWTH AND SIGNIFICANT PIPELINE PROGRESS FOR FULL-YEAR 2018

BRIEF-Basilea Pharmaceutica: Strong European Cresemba Sales Trigger $5 Mln Milestone Payment

* STRONG EUROPEAN CRESEMBA® (ISAVUCONAZOLE) SALES TRIGGER USD 5 MILLION MILESTONE PAYMENT TO BASILEA FROM PFIZER

BRIEF-Basilea Says Adesh Kaul Appointed CFO

* BASILEA ANNOUNCES CHANGE IN THE MANAGEMENT COMMITTEE - ADESH KAUL APPOINTED CFO

BRIEF-Basilea Announces Collaboration To Study Derazantinib And Atezolizumab In Urothelial Cancer

* BASILEA ANNOUNCES COLLABORATION TO STUDY DERAZANTINIB AND ATEZOLIZUMAB (TECENTRIQ®) IN UROTHELIAL CANCER

BRIEF-Basilea Announces Collaboration To Study Derazantinib And Atezolizumab In Urothelial Cancer

* BASILEA ANNOUNCES COLLABORATION TO STUDY DERAZANTINIB AND ATEZOLIZUMAB (TECENTRIQ®) IN UROTHELIAL CANCER

BRIEF-Basilea: Positive Interim Results From Registrational Phase 2 Study With Derazantinib

* BASILEA REPORTS POSITIVE INTERIM RESULTS FROM REGISTRATIONAL PHASE 2 STUDY WITH ONCOLOGY DRUG CANDIDATE DERAZANTINIB IN INTRAHEPATIC CHOLANGIOCARCINOMA (ICCA)

BRIEF-Basilea Preliminary FY Revenue At CHF 133 Mln

* BASILEA REPORTS STRONG, HIGHER THAN EXPECTED PRELIMINARY REVENUE OF CHF 133 MILLION FOR FINANCIAL YEAR 2018

BRIEF-Basilea Pharmaceutica: CHF 10 Million Milestone Payment For Cresemba Sales

* CONTINUED STRONG CRESEMBA® (ISAVUCONAZOLE) U.S. SALES PERFORMANCE BY ASTELLAS PHARMA INC. TRIGGERS CHF 10 MILLION MILESTONE PAYMENT TO BASILEA

BRIEF-Basilea Presents Preclinical Data On Anticancer Drug Candidate Bal101553 At Eortc-Nci-Aacr Symposium

* BASILEA PRESENTS PRECLINICAL DATA ON ITS ANTICANCER DRUG CANDIDATE BAL101553 AT EORTC-NCI-AACR SYMPOSIUM Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Select another date: